Regeneron Pharmaceuticals Aktie
| 785,04USD | 18,49USD | 2,41% |
WKN: 881535 / ISIN: US75886F1075
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 10 368 | 11 851 | 13 450 | 15 106 | 15 410 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,55 | 1,03 | 0,98 | 0,94 | 0,93 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 14 015 | 15 884 | 19 479 | 18 661 | 18 022 |
| Summe Anlagevermögen | 11 420 | 13 389 | 13 651 | 19 192 | 22 537 |
| Summe Aktiva | 25 435 | 29 273 | 33 131 | 37 852 | 40 559 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 6 666 | 6 609 | 7 158 | 8 499 | 9 302 |
| Summe Eigenkapital | 18 769 | 22 664 | 25 973 | 29 354 | 31 257 |
| Summe Passiva | 25 435 | 29 273 | 33 131 | 37 852 | 40 559 |
Adresse
| 777 Old Saw Mill River Road, 10591-6707 Tarrytown | |
| Telefon | +1 (914) 847-7000 |
| Internet | http://www.regeneron.com |
Management
|
Andrew J. Murphy
Executive Vice President-Research |
|
Arthur Frederick Ryan
Independent Director |
|
Benjamin Drosman
SVP-Regulatory Compliance & Global Development |
|
Boaz Hirshberg
SVP-Clinical Development Unit Head |
|
Bob McCowan
Chief Information Officer & Senior VP-IT |
|
Bolanle Akinlade
Senior Vice President-Medical Affairs |
|
Bonnie L. Bassler
Independent Director |
|
Christina Chan
Senior Vice President-Corporate Affairs |
|
Christine A. Poon
Lead Independent Director |
|
Christopher Robert Fenimore
Chief Financial Officer & Executive VP-Finance |
|
Christos Kyratsous
SVP & Co-Head-Regeneron Genetic Medicines |
|
Craig B. Thompson
Independent Director |
|
Daniel P. van Plew
EVP, GM-Industrial Operations & Product Supply |
|
David Paul Schenkein
Independent Director |
|
David Simon
Senior Vice President-Business Operations |
|
George Damis Yancopoulos
Co-Chairman & Co-President |
|
George L. Sing
Independent Director |
|
Huda Y. Zoghbi
Independent Director |
|
John Calabro
Senior Vice President-Internal Audit |
|
Joseph J. LaRosa
Secretary, Executive VP & General Counsel |
|
Joseph L. Goldstein
Independent Director |
|
Kathryn W. Guarini
Independent Director |
|
Kerry K. Reinertsen
Senior Vice President-Strategic Alliances |
|
Leonard Brooks
Treasurer & Senior Vice President |
|
Leonard S. Schleifer
Co-Chairman, Co-President & CEO |
|
Lori Morton
Senior Vice President-Research |
|
Lynn Macdonald
Senior Vice President-Research |
|
Marion McCourt
Executive Vice President-Commercial |
|
Mark Hudson
Head-Investor Relations |
|
Mark Volpe
Senior Vice President-Tax |
|
Maya Bermingham
Senior VP-Public Policy & Government Affairs |
|
Melissa Lozner
Chief Compliance Officer & Senior Vice President |
|
Michael S. Brown
Independent Director |
|
N. Anthony Coles
Independent Director |
|
Ned Braunstein
EVP-Regulatory Affairs & Global Patient Safety |
|
Nouhad Husseini
Senior VP-Business Development |
|
Rajesh Ahuja
SVP-Quality Assurance & Operations |
|
Rick Hall
Senior Vice President-Human Resources |
|
Ryan Crowe
SVP-Investor Relations & Strategic Analysis |
|
Sally A. Paull
Executive Vice President-Human Resources |
|
Smita Pillai
SVP-Talent Development & Innovation Culture |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.